BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
RoboCT, a technology-driven enterprise, takes technology innovation as its core driving force and is committed to exoskeleton robot technology, robot core components and intelligent control technology. They focus on the fields of rehabilitation and elderly care through the combination of human-computer interaction technology, artificial intelligence technology, data analysis and cloud computing, providing intelligent products and solutions for medical and healthcare institutions and individual users.
Website
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.